Evidence map›Paper›PMID 34035105›Full record

ArticleBMJ open2021

Measuring the impact of COVID-19 on the quality of life of the survivors, partners and family members: a cross-sectional international online survey.

Rubina Shah, Faraz M Ali, Stuart J Nixon, John R Ingram, Sam M Salek, Andrew Y Finlay

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Validation of the FROM-16 in family members of patients receiving advanced therapy medicinal product (ATMP).Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rubina ShahDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK ShahR45@cardiff.ac.uk.ORCID 0000-0001-8158-712X
Faraz M AliDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0002-4184-2023
Stuart J NixonMultiple Sclerosis Society, Cardiff, UK.
John R IngramDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0002-5257-1142
Sam M SalekSchool of Life & Medical Sciences, University of Hertfordshire, Hatfield, UK.ORCID 0000-0002-4612-5699
Andrew Y FinlayDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.ORCID 0000-0003-2143-1646
Cardiff University · GBMultiple Sclerosis Society · GBUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to measure the impact of COVID-19 on the quality of life (QoL) of survivors and their partners and family members. DESIGN AND

settingA prospective cross-sectional global online survey using social media.

participantsPatients with COVID-19 and partners or family members (age ≥18 years).

interventionOnline survey from June to August 2020.

main outcome measureThe EuroQol group five dimensions three level (EQ-5D-3L) to measure the QoL of survivors of COVID-19, and the Family Reported Outcome Measure (FROM-16) to assess the impact on their partner/family member's QoL.

resultsThe survey was completed by 735 COVID-19 survivors (mean age=48 years; females=563) at a mean of 12.8 weeks after diagnosis and by 571 partners and 164 family members (n=735; mean age=47 years; females=246) from Europe (50.6%), North America (38.5%) and rest of the world (10.9%). The EQ-5D mean score for COVID-19 survivors was 8.65 (SD=1.9, median=9; range=6-14). 81.1% (596/735) reported pain and discomfort, 79.5% (584/735) problems with usual activities, 68.7% (505/735) anxiety and depression and 56.2% (413/735) problems with mobility. Hospitalised survivors (20.1%, n=148) and survivors with existing health conditions (30.9%, n=227) reported significantly more problems with mobility and usual activities (p<0.05), with hospitalised also experiencing more impact on self-care (p≤0.001). Among 735 partners and family members, the mean FROM-16 score (maximum score=highest impact =32) was 15 (median=15, range=0-32). 93.6% (688/735) reported being worried, 81.7% (601/735) frustrated, 78.4% (676/735) sad, 83.3% (612/735) reported impact on their family activities, 68.9% (507/735) on sleep and 68.1% (500/735) on their sex life.

conclusionCOVID-19 survivors reported a major persisting impact on their physical and psychosocial health. The lives of their partners and other family members were also severely affected. There is a need for a holistic support system sensitive to the needs of COVID-19 survivors and their family members who experience a major 'secondary burden'.

Indexed as

COVID-19Quality of LifeAdolescentCross-Sectional StudiesEuropeFamilyFemaleHumansMiddle AgedNorth AmericaProspective StudiesSARS-CoV-2Surveys and QuestionnairesSurvivorsCOVID-19infection controlpublic health

Identifiers

PMID34035105
PMCPMC8154981
OpenAlexW3164000035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.